Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)

Avalo Therapeutics filings provide 5 years of Intangibles readings, the most recent being $38000.0 for Q4 2021.

  • On a quarterly basis, Intangibles fell 97.6% to $38000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $38000.0, a 97.6% decrease, with the full-year FY2021 number at $38000.0, down 97.6% from a year prior.
  • Intangibles hit $38000.0 in Q4 2021 for Avalo Therapeutics, down from $304000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $33.1 million in Q1 2018 to a low of $38000.0 in Q4 2021.
  • Median Intangibles over the past 5 years was $2.4 million (2019), compared with a mean of $12.6 million.
  • The widest YoY moves for Intangibles: up 29.0% in 2021, down 97.6% in 2021.
  • Avalo Therapeutics' Intangibles stood at $17.7 million in 2017, then crashed by 78.68% to $3.8 million in 2018, then crashed by 35.57% to $2.4 million in 2019, then tumbled by 34.67% to $1.6 million in 2020, then plummeted by 97.6% to $38000.0 in 2021.
  • The last three reported values for Intangibles were $38000.0 (Q4 2021), $304000.0 (Q3 2021), and $732000.0 (Q2 2021) per Business Quant data.